Sustained nitric oxide-releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells, preventing biofilm formation in vitro and in a rodent central venous catheter model

Mohammed S. Ahmadi, Hiu Ham Lee, David A. Sanchez, Adam J. Friedman, Moses T. Tar, Kelvin Davies, Joshua D. Nosanchuk, Luis R. Martinez

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Candida albicans is a leading nosocomial pathogen. Today, candidal biofilms are a significant cause of catheter infections, and such infections are becoming increasingly responsible for the failure of medical-implanted devices. C. albicans forms biofilms in which fungal cells are encased in an autoproduced extracellular polysaccharide matrix. Consequently, the enclosed fungi are protected from antimicrobial agents and host cells, providing a unique niche conducive to robust microbial growth and a harbor for recurring infections. Here we demonstrate that a recently developed platform comprised of nanoparticles that release therapeutic levels of nitric oxide (NO-np) inhibits candidal biofilm formation, destroys the extracellular polysaccharide matrices of mature fungal biofilms, and hinders biofilm development on surface biomaterials such as the lumen of catheters. We found NO-np to decrease both the metabolic activity of biofilms and the cell viability of C. albicans in vitro and in vivo. Furthermore, flow cytometric analysis found NO-np to induce apoptosis in biofilm yeast cells in vitro. Moreover, NO-np behave synergistically when used in combination with established antifungal drug therapies. Here we propose NO-np as a novel treatment modality, especially in combination with standard antifungals, for the prevention and/or remediation of fungal biofilms on central venous catheters and other medical devices.

Original languageEnglish (US)
Pages (from-to)2185-2194
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Central Venous Catheters
Biofilms
Candida albicans
Nanoparticles
Rodentia
Nitric Oxide
Cell Death
Yeasts
Extracellular Matrix
Polysaccharides
Catheters
Infection
Equipment Failure
In Vitro Techniques
Biocompatible Materials
Anti-Infective Agents
Cell Survival
Fungi
Apoptosis
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Sustained nitric oxide-releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells, preventing biofilm formation in vitro and in a rodent central venous catheter model. / Ahmadi, Mohammed S.; Lee, Hiu Ham; Sanchez, David A.; Friedman, Adam J.; Tar, Moses T.; Davies, Kelvin; Nosanchuk, Joshua D.; Martinez, Luis R.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 4, 01.04.2016, p. 2185-2194.

Research output: Contribution to journalArticle

@article{c5db301ffb00490eba10f8cb4d76bf14,
title = "Sustained nitric oxide-releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells, preventing biofilm formation in vitro and in a rodent central venous catheter model",
abstract = "Candida albicans is a leading nosocomial pathogen. Today, candidal biofilms are a significant cause of catheter infections, and such infections are becoming increasingly responsible for the failure of medical-implanted devices. C. albicans forms biofilms in which fungal cells are encased in an autoproduced extracellular polysaccharide matrix. Consequently, the enclosed fungi are protected from antimicrobial agents and host cells, providing a unique niche conducive to robust microbial growth and a harbor for recurring infections. Here we demonstrate that a recently developed platform comprised of nanoparticles that release therapeutic levels of nitric oxide (NO-np) inhibits candidal biofilm formation, destroys the extracellular polysaccharide matrices of mature fungal biofilms, and hinders biofilm development on surface biomaterials such as the lumen of catheters. We found NO-np to decrease both the metabolic activity of biofilms and the cell viability of C. albicans in vitro and in vivo. Furthermore, flow cytometric analysis found NO-np to induce apoptosis in biofilm yeast cells in vitro. Moreover, NO-np behave synergistically when used in combination with established antifungal drug therapies. Here we propose NO-np as a novel treatment modality, especially in combination with standard antifungals, for the prevention and/or remediation of fungal biofilms on central venous catheters and other medical devices.",
author = "Ahmadi, {Mohammed S.} and Lee, {Hiu Ham} and Sanchez, {David A.} and Friedman, {Adam J.} and Tar, {Moses T.} and Kelvin Davies and Nosanchuk, {Joshua D.} and Martinez, {Luis R.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1128/AAC.02659-15",
language = "English (US)",
volume = "60",
pages = "2185--2194",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Sustained nitric oxide-releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells, preventing biofilm formation in vitro and in a rodent central venous catheter model

AU - Ahmadi, Mohammed S.

AU - Lee, Hiu Ham

AU - Sanchez, David A.

AU - Friedman, Adam J.

AU - Tar, Moses T.

AU - Davies, Kelvin

AU - Nosanchuk, Joshua D.

AU - Martinez, Luis R.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Candida albicans is a leading nosocomial pathogen. Today, candidal biofilms are a significant cause of catheter infections, and such infections are becoming increasingly responsible for the failure of medical-implanted devices. C. albicans forms biofilms in which fungal cells are encased in an autoproduced extracellular polysaccharide matrix. Consequently, the enclosed fungi are protected from antimicrobial agents and host cells, providing a unique niche conducive to robust microbial growth and a harbor for recurring infections. Here we demonstrate that a recently developed platform comprised of nanoparticles that release therapeutic levels of nitric oxide (NO-np) inhibits candidal biofilm formation, destroys the extracellular polysaccharide matrices of mature fungal biofilms, and hinders biofilm development on surface biomaterials such as the lumen of catheters. We found NO-np to decrease both the metabolic activity of biofilms and the cell viability of C. albicans in vitro and in vivo. Furthermore, flow cytometric analysis found NO-np to induce apoptosis in biofilm yeast cells in vitro. Moreover, NO-np behave synergistically when used in combination with established antifungal drug therapies. Here we propose NO-np as a novel treatment modality, especially in combination with standard antifungals, for the prevention and/or remediation of fungal biofilms on central venous catheters and other medical devices.

AB - Candida albicans is a leading nosocomial pathogen. Today, candidal biofilms are a significant cause of catheter infections, and such infections are becoming increasingly responsible for the failure of medical-implanted devices. C. albicans forms biofilms in which fungal cells are encased in an autoproduced extracellular polysaccharide matrix. Consequently, the enclosed fungi are protected from antimicrobial agents and host cells, providing a unique niche conducive to robust microbial growth and a harbor for recurring infections. Here we demonstrate that a recently developed platform comprised of nanoparticles that release therapeutic levels of nitric oxide (NO-np) inhibits candidal biofilm formation, destroys the extracellular polysaccharide matrices of mature fungal biofilms, and hinders biofilm development on surface biomaterials such as the lumen of catheters. We found NO-np to decrease both the metabolic activity of biofilms and the cell viability of C. albicans in vitro and in vivo. Furthermore, flow cytometric analysis found NO-np to induce apoptosis in biofilm yeast cells in vitro. Moreover, NO-np behave synergistically when used in combination with established antifungal drug therapies. Here we propose NO-np as a novel treatment modality, especially in combination with standard antifungals, for the prevention and/or remediation of fungal biofilms on central venous catheters and other medical devices.

UR - http://www.scopus.com/inward/record.url?scp=84963757827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963757827&partnerID=8YFLogxK

U2 - 10.1128/AAC.02659-15

DO - 10.1128/AAC.02659-15

M3 - Article

VL - 60

SP - 2185

EP - 2194

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -